There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Accolade (ACCD – Research Report) and Resmed (RMD – Research Report) with bullish sentiments.
Accolade (ACCD)
Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade today and set a price target of $13.00. The company’s shares closed last Thursday at $9.19.
According to TipRanks.com, MacDonald is a 5-star analyst with an average return of
Accolade has an analyst consensus of Moderate Buy, with a price target consensus of $12.83, representing a 39.9% upside. In a report issued on April 18, Leerink Partners also maintained a Buy rating on the stock with a $16.00 price target.
See the top stocks recommended by analysts >>
Resmed (RMD)
In a report released today, Michael Matson from Needham reiterated a Buy rating on Resmed, with a price target of $236.00. The company’s shares closed last Thursday at $183.42.
According to TipRanks.com, Matson ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Resmed has an analyst consensus of Strong Buy, with a price target consensus of $217.67, implying a 18.9% upside from current levels. In a report released today, KeyBanc also maintained a Buy rating on the stock with a $238.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACCD:
